Epigenomics (EPGNY) vs. Its Peers Head-To-Head Comparison

Epigenomics (OTCMKTS:EPGNYGet Free Report) is one of 67 publicly-traded companies in the “Diagnostics & Research” industry, but how does it contrast to its rivals? We will compare Epigenomics to related businesses based on the strength of its dividends, analyst recommendations, institutional ownership, earnings, profitability, valuation and risk.


This table compares Epigenomics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Epigenomics N/A N/A N/A
Epigenomics Competitors -832.40% -1,160.25% -24.25%

Valuation & Earnings

This table compares Epigenomics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Epigenomics N/A N/A -0.78
Epigenomics Competitors $733.33 million $27.70 million 372.33

Epigenomics’ rivals have higher revenue and earnings than Epigenomics. Epigenomics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

28.3% of shares of all “Diagnostics & Research” companies are held by institutional investors. 30.5% of shares of all “Diagnostics & Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Epigenomics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Epigenomics 0 0 0 0 N/A
Epigenomics Competitors 74 270 284 3 2.34

As a group, “Diagnostics & Research” companies have a potential upside of 71.12%. Given Epigenomics’ rivals higher probable upside, analysts clearly believe Epigenomics has less favorable growth aspects than its rivals.


Epigenomics rivals beat Epigenomics on 5 of the 8 factors compared.

About Epigenomics

(Get Free Report)

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Receive News & Ratings for Epigenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epigenomics and related companies with MarketBeat.com's FREE daily email newsletter.